IQVIA (NYSE:IQV) Sees Large Volume Increase – Still a Buy?

Shares of IQVIA Holdings Inc. (NYSE:IQV) saw unusually-high trading volume on Monday . Approximately 872,396 shares traded hands during trading, an increase of 53% from the previous session’s volume of 569,620 shares.The stock last traded at $201.98 and had previously closed at $197.39.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent research reports. Stephens initiated coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. TD Cowen decreased their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Finally, JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Stock Performance

The business’s fifty day moving average price is $202.22 and its 200-day moving average price is $221.94. The stock has a market cap of $37.07 billion, a PE ratio of 26.81, a P/E/G ratio of 2.05 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Institutional Investors Weigh In On IQVIA

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nordea Investment Management AB raised its holdings in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. GAMMA Investing LLC raised its stake in shares of IQVIA by 27.7% in the fourth quarter. GAMMA Investing LLC now owns 1,406 shares of the medical research company’s stock worth $276,000 after buying an additional 305 shares during the period. Versant Capital Management Inc lifted its position in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in IQVIA by 0.8% in the 3rd quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company’s stock worth $49,532,000 after acquiring an additional 1,750 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.